SCHEMBL24329339

SCHEMBL24329339

COC(=O)c1cc(F)c(C)cc1OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.50
KDM4E B2RXH2 7/20 0.47
HTT P42858 2/20 0.47
ALDH1A1 P00352 3/20 0.45
HPGD P15428 3/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
POLB P06746 3/20 0.44
KMT2A Q03164 2/20 0.41
LMNA P02545 2/20 0.41
MAPT P10636 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
HSD17B10 Q99714 2/20 0.41
USP2 O75604 1/20 0.41
RECQL P46063 1/20 0.40
TUBB1 Q9H4B7 1/20 0.39
FGFR1 P11362 1/20 0.39
SRC P12931 1/20 0.39
MEN1 O00255 1/20 0.39
RAB9A P51151 2/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29555441 1.00 GAA (0.50) GAAKDM4EHTTALDH1A1HPGD
SCHEMBL23704095 0.87 GAA (0.54) GAAKDM4EHTTALDH1A1HPGD
SCHEMBL14032887 0.86 KDM4E (0.47) GAAKDM4EHTTALDH1A1HPGD
SCHEMBL28934458 0.85 KDM4E (0.46) GAAKDM4EHTTALDH1A1HPGD
SCHEMBL3436881 0.85 MAPT (0.42) GAAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL31024710 0.85 MAPT (0.42) GAAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL18713914 0.84 ALDH1A1 (0.51) KDM4EHTTALDH1A1HPGDPOLB
SCHEMBL365903 0.83 MAPT (0.41) GAAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL21932887 0.83 PDGFRB (0.42) GAAKDM4EALDH1A1HPGDPOLB
SCHEMBL6781993 0.83 KDM4E (0.56) GAAKDM4EHTTALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250263402-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) 2025-08-21 US disclosed
EP-4227299-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (CN) 2023-08-16 EP disclosed
EP-4227299-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (CN) 2023-08-16 EP disclosed
WO-2022078152-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF 杭州中美华东制药有限公司 2022-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250263402-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF GLP1R, GIPR, GCGR GAA 2290/4885KDM4E 3230/4885HTT 2553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.